Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747221 | 0.99 | SLC18A3 (0.31) | KIF11SLC18A3SIGMAR1 | |
| SCHEMBL25544064 | 0.85 | HRH3 (0.34) | SLC18A3SIGMAR1 | |
| SCHEMBL21765831 | 0.85 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL21747211 | 0.85 | SLC18A3 (0.33) | SLC18A3SIGMAR1 | |
| SCHEMBL25544105 | 0.84 | HRH3 (0.35) | SLC18A3SIGMAR1 | |
| SCHEMBL21765676 | 0.84 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL21747399 | 0.83 | SLC18A3 (0.34) | SLC18A3SIGMAR1 | |
| SCHEMBL21747292 | 0.77 | MME (0.36) | — | |
| SCHEMBL21747416 | 0.76 | ITGB1 (0.35) | — | |
| SCHEMBL21747370 | 0.75 | EGLN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| EP-3613742-B1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | KIF11 1829/4885SLC18A3 410/4885SIGMAR1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.